TY - JOUR
T1 - Dupilumab therapy in atopic dermatitis is safe during COVID-19 infection era
T2 - A systematic review and meta-analysis of 1611 patients
AU - El-Qushayri, Amr Ehab
AU - Mahmoud, Mariam Abdelmageed
AU - Salman, Samar
AU - Sarsik, Sameh
AU - Nardone, Beatrice
N1 - Publisher Copyright:
© 2022 Wiley Periodicals LLC.
PY - 2022/6
Y1 - 2022/6
N2 - The aim of this meta-analysis is to evaluate the safety of dupilumab use in the management of atopic dermatitis (AD) during the current pandemic regarding the risk and the hazards of COVID-19 infection. Seven databases (Google Scholar, Web of Science, Scopus, Virtual Health Library, PubMed, System for Information on Gray Literature in Europe, and The New York Academy of Medicine) were searched for eligible studies from inception until November 24, 2021. The quality of evidence was rated using the National Institute of Health and the Joanna Briggs Institute Critical Appraisal tool. Meta-analysis was performed when the outcome is presented ≥2 studies. A total of 12 papers including 1611 AD patients were included in the study. The prevalence of COVID-19 in AD treated with dupilumab was 3.2% (95% confidence interval [CI]: 1.7–5.8). COVID-19 symptoms were reported by five patients who were presented with one or more of the following symptoms (fatigue, loss of taste and smell, runny nose, conjunctivitis, gastrointestinal symptoms, fever, cough, and dyspnea). Only three cases of COVID-19 were hospitalized with a prevalence of 4.5%, while no patients with COVID-19 died. Dupilumab is safe regarding the risk and the hazards of COVID-19 in AD patients. Thus, based on these results continuation of dupilumab in AD patients is recommended, since dupilumab seems to be safe and crucial for a better disease outcome.
AB - The aim of this meta-analysis is to evaluate the safety of dupilumab use in the management of atopic dermatitis (AD) during the current pandemic regarding the risk and the hazards of COVID-19 infection. Seven databases (Google Scholar, Web of Science, Scopus, Virtual Health Library, PubMed, System for Information on Gray Literature in Europe, and The New York Academy of Medicine) were searched for eligible studies from inception until November 24, 2021. The quality of evidence was rated using the National Institute of Health and the Joanna Briggs Institute Critical Appraisal tool. Meta-analysis was performed when the outcome is presented ≥2 studies. A total of 12 papers including 1611 AD patients were included in the study. The prevalence of COVID-19 in AD treated with dupilumab was 3.2% (95% confidence interval [CI]: 1.7–5.8). COVID-19 symptoms were reported by five patients who were presented with one or more of the following symptoms (fatigue, loss of taste and smell, runny nose, conjunctivitis, gastrointestinal symptoms, fever, cough, and dyspnea). Only three cases of COVID-19 were hospitalized with a prevalence of 4.5%, while no patients with COVID-19 died. Dupilumab is safe regarding the risk and the hazards of COVID-19 in AD patients. Thus, based on these results continuation of dupilumab in AD patients is recommended, since dupilumab seems to be safe and crucial for a better disease outcome.
KW - COVID-19
KW - atopic dermatitis
KW - dupilumab
KW - meta-analysis
UR - http://www.scopus.com/inward/record.url?scp=85127575496&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127575496&partnerID=8YFLogxK
U2 - 10.1111/dth.15476
DO - 10.1111/dth.15476
M3 - Review article
C2 - 35357060
AN - SCOPUS:85127575496
SN - 1396-0296
VL - 35
JO - Dermatologic Therapy
JF - Dermatologic Therapy
IS - 6
M1 - e15476
ER -
